Table III.

Associations between Runx, MAPK1, eIF4E and colon tumor mutations

HRG	MAPK1	RUNX2	RUNX1		CIMP+
	rs11913721 (A > C)	rs12333172 (C > T)	rs2071029 (G > A)		Controls	Cases	OR	(95% CI)
	CC	TT	GA/AA		Na	Nb
1	*				295	55	1.44	(1.04, 1.99)
1		*			65	20	2.32	(1.37, 3.92)
1			*		559	94	1.32	(1.00, 1.73)
2	*	*			13	1	0.55	(0.07, 4.28)
2	*		*		83	20	1.93	(1.14, 3.26)
2		*	*		17	5	2.51	(0.90, 7.00)
3	*	*	*		2	0	undefined
	RUNX2	RUNX3	EIF4EBP2	RUNX1	KRAS2
	rs10948238 (C > T)	rs6672420 (A > T)	rs7078987 (A > G)	rs8134380 (A > T)	Controls	Cases	OR	(95% CI)
	TT	AA/AT	GG	AA	N	Nc
1	*				316	81	1.55	(1.18, 2.05)
1		*			1504	284	1.35	(1.01, 1.81)
1			*		413	88	1.36	(1.04, 1.78)
1				*	605	144	1.53	(1.21, 1.94)
2	*	*			255	62	2.09	(1.37, 3.18)
2	*		*		69	18	1.85	(1.07, 3.19)
2	*			*	94	34	2.51	(1.61, 3.91)
2		*	*		321	71	1.81	(1.21, 2.73)
2		*		*	469	113	2.26	(1.49, 3.43)
2			*	*	123	39	2.24	(1.50, 3.35)
3	*	*	*		58	13	2.21	(1.08, 4.50)
3	*	*		*	77	28	4.59	(2.39, 8.82)
3	*		*	*	18	10	4.54	(2.01, 10.25)
3		*	*	*	96	30	3.48	(1.90, 6.36)
4	*	*	*	*	16	8	8.66	(2.99, 25.09)
	RUNX2	RUNX1	EIF4EBP3	RUNX3	TP53
	rs12333172 (C > T)	rs2248720 (A > C)	rs250425 (C > T)	rs6672420 (A > T)	Controls	Cases	OR	(95% CI)
	TT	AA	CC	AA	N	Nd
1	*				65	29	1.76	(1.12, 2.76)
1		*			503	162	1.29	(1.04, 1.60)
1			*		1120	328	1.30	(1.06, 1.60)
1				*	495	167	1.44	(1.17, 1.79)
2	*	*			11	7	2.65	(1.01, 6.92)
2	*		*		31	18	2.72	(1.48, 5.00)
2	*			*	17	14	3.56	(1.73, 7.33)
2		*	*		273	102	1.71	(1.26, 2.33)
2		*		*	136	52	1.74	(1.22, 2.48)
2			*	*	282	108	1.88	(1.40, 2.53)
3	*	*	*		3	6	11.35	(2.69, 47.88)
3	*	*		*	4	4	4.55	(1.12, 18.55)
3	*		*	*	8	9	5.89	(2.19, 15.81)
3		*	*	*	79	30	1.78	(1.09, 2.92)
4	*	*	*	*	1	3	17.80	(1.73, 183.42)
	RUNX1	EIF4EBP2	RUNX3	MAPK1	MSI+
	rs2242878 (C > T)	rs7078987 (A > G)	rs906296 (C > G)	rs9610375 (G > T)	Controls	Cases	OR	(95% CI)
	CT/TT	AA/AG	GG	GG	N	Ne
1	*				638	80	1.60	(1.17, 2.17)
1		*			1514	156	1.51	(1.00, 2.30)
1			*		115	17	1.58	(0.92, 2.69)
1				*	559	72	1.60	(1.17, 2.18)
2	*	*			485	64	2.66	(1.44, 4.94)
2	*		*		35	8	2.82	(1.26, 6.31)
2	*			*	194	36	2.68	(1.73, 4.14)
2		*	*		90	14	2.27	(1.13, 4.57)
2		*		*	429	57	2.91	(1.56, 5.45)
2			*	*	29	4	1.77	(0.61, 5.15)
3	*	*	*		25	7	7.07	(2.38, 21.01)
3	*	*		*	145	27	5.16	(2.16, 12.35)
3	*		*	*	9	1	1.39	(0.17, 11.29)
3		*	*	*	23	3	3.49	(0.88, 13.83)
4	*	*	*	*	5	1	6.88	(0.63, 75.06)
	RUNX2	EIF4E	RUNX1		CIMP+ and KRAS2
	rs10948238 (C > T)	rs11727086 (A > G)	rs1474479 (G > A)		Controls	Cases	OR	(95% CI)
	TT	AG/GG	GG/GA		N	Nf
1	*				316	19	1.79	(1.04, 3.07)
1		*			839	40	1.68	(1.04, 2.71)
1			*		1705	70	2.53	(0.91, 7.00)
2	*	*			125	13	3.63	(1.81, 7.30)
2	*		*		268	19	3.27	(1.08, 9.90)
2		*	*		721	38	3.38	(0.80, 14.31)
3	*	*	*		103	13	7.47	(1.58, 35.32)
	RUNX2	RUNX1	MAPK1	RUNX3	CIMP+ and MSI+
	rs1321075 (C > A)	rs2242878 (C > T)	rs8136867 (A > G)	rs906296 (C > G)	Controls	Cases	OR	(95% CI)
	CC	CT/TT	GG	GG	N	Ng
1	*				1437	90	1.75	(1.04, 2.94)
1		*			638	52	1.94	(1.31, 2.87)
1			*		411	39	2.20	(1.46, 3.33)
1				*	115	13	2.03	(1.10, 3.76)
2	*	*			463	44	3.30	(1.61, 6.77)
2	*		*		320	30	5.75	(2.55, 12.94)
2	*			*	86	12	3.75	(1.72, 8.21)
2		*	*		146	19	4.21	(2.30, 7.68)
2		*		*	35	6	4.07	(1.61, 10.33)
2			*	*	20	3	3.91	(1.09, 14.00)
3	*	*	*		105	14	9.75	(3.14, 30.31)
3	*	*		*	22	6	11.00	(3.37, 35.96)
3	*		*	*	14	2	10.30	(1.78, 59.71)
3		*	*	*	7	1	4.36	(0.50, 38.03)
4	*	*	*	*	3	1	76.32	(3.10, 1879.34)

HRG, high-risk genotypes. Rows are not mutually exclusive and include all individuals with the starred high-risk genotype versus those without any of the starred high-risk genotypes.

^a1956 controls total.

^b272 CIMP+ cases total.

^c348 KRAS2 cases total.

^d516 TP53 cases total.

^e185 MSI+ cases total.

^f74 CIMP+ and KRAS2 cases total.

^g108 CIMP and MSI+ cases total.